Screenshot 2014-08-08 at 09.50.18< /a>

CIC biomaGUNE and IK4-CIDETEC are immersed in the European project PneumoNP, in which, together with research centers, universities and companies from six European countries, they work to fight antibiotic resistance in some infections.

This research topic is particularly important since according to data from the World Health Organization (WHO) The global threat of antibiotic resistance is not a long-term prediction, but a reality that affects every region of the world and potentially people of any age.

The antibiotics developed within the framework of this European project are designed to bind to specific nanovehicles that allow the drug to be directed more efficiently to the bacteria that cause infections in the respiratory system . Within this framework, CIC biomaGUNE will carry out studies to determine the efficiency of the new administration system and the biodistribution of the new drugs in vivo, and K4-CIDETEC will be involved in the synthesis of polymeric nanoparticles that They will serve as a vehicle for the drug to reach the lung, as well as in the production of new nanotherapeutic complexes (nanoparticle + drug).